In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
Toshiki Tsuboi, Keita Hattori, Takuji Ishimoto, Kentaro Imai, Tomohito Doke, Junichiro Hagita, Jumpei Ariyoshi, Kazuhiro Furuhashi, Noritoshi Kato, Yasuhiko Ito, Yukiko Kamiya, Hiroyuki Asanuma, Shoichi Maruyama
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCRISPR and Genetic Engineering · Renal and related cancers · Pluripotent Stem Cells Research
Main text
(Molecular Therapy: Nucleic Acids 36, 102387; ▪▪)
In the originally published version of this article, there was an error in Table S1. The authors mistakenly omitted data for urinary glucose. The results for urinary glucose are as follows, and can be found within the revised table:
Urinary glucose (mg/mgCr)(mean ± SEM)
PBS 0.57 ± 0.03
SNA2-ASO 5.54 ± 0.95
MOE-ASO 7.64 ± 1.79